Skip to Main Content


Skip Nav Destination

Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

Cancer Res (2020) 80 (16_Supplement): CT130.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Fen Wang
  • Mingyi Yang
  • Weichi Luo
  • Qing Zhou
Journal of the National Cancer Center (2022) 2 (4): 243.
  • Tania Crombet Ramos
  • Orestes Santos Morales
  • Grace K. Dy
  • Kalet León Monzón
  • Agustín Lage Dávila
Frontiers in Oncology (2021) 11
Close Modal

or Create an Account

Close Modal
Close Modal